Generated by AI
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on oral drug delivery solutions for medications that are traditionally administered by injection. The company develops proprietary technologies designed to make therapeutic proteins and peptides easier to administer in capsule form, with a particular emphasis on diabetes-related treatments and other biologic therapies. Its current product and development portfolio includes oral insulin programs, along with partnering and licensing activities that support broader applications for its delivery platform. Oramed Pharmaceuticals Inc. also participates in strategic collaborations and investment transactions tied to its biomedical assets, reflecting a business model that combines drug development with portfolio-based value creation. Headquartered in New York, the company operates within the pharmaceuticals and biotechnology market, where oral delivery platforms can play an important role in improving convenience and expanding the usability of complex medicines.
Website1185 Avenue of the Americas
New York, NY, 10036
United States
The latest articles about ORMP.
Tipranks Press Release.
Summary of Jul 23's posts. Generated by AI.
Summary of May 19's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about ORMP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.